{
    "title": "110_hr3689",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Ovarian Cancer Biomarker Research \nAct of 2007''.\n\nSEC. 2. GRANTS FOR ESTABLISHMENT AND OPERATION OF RESEARCH CENTERS FOR \n              THE STUDY OF OVARIAN CANCER BIOMARKERS.\n\n    Subpart 1 of part C of the Public Health Service Act is amended by \nadding at the end the following new section:\n\n``SEC. 417E. GRANTS FOR ESTABLISHMENT AND OPERATION OF RESEARCH CENTERS \n              FOR THE STUDY OF OVARIAN CANCER BIOMARKERS.\n\n    ``(a) In General.--The Director of the Institute, in consultation \nwith the directors of other relevant institutes and centers of the \nNational Institutes of Health and the Department of Defense Ovarian \nCancer Research Program, shall enter into cooperative agreements with, \nor make grants to, public or nonprofit entities to establish and \noperate centers to conduct research on biomarkers for use in risk \nstratification for, and the early detection and screening of, ovarian \ncancer, including fallopian tube cancer or primary peritoneal cancer. \nEach center shall be known as an Ovarian Cancer Biomarker Center of \nExcellence.\n    ``(b) Research Funded.--Federal payments made under a cooperative \nagreement or grant under subsection (a) may be used for research on any \nof the following:\n            ``(1) The development and characterization of new \n        biomarkers, and the refinement of existing biomarkers, for \n        ovarian cancer.\n            ``(2) The clinical and laboratory validation of such \n        biomarkers, including technical development, standardization of \n        assay methods, sample preparation, reagents, reproducibility, \n        portability, and other refinements.\n            ``(3) The development and implementation of clinical and \n        epidemiological research on the utilization of biomarkers for \n        the early detection and screening of ovarian cancer.\n            ``(4) The development and implementation of repositories \n        for new tissue, urine, serum, and other biological specimens \n        (such as ascites and pleural fluids).\n    ``(c) First Agreement or Grant.--Not later than 1 year after the \ndate of the enactment of this section, the Director of the Institute \nshall enter into the first cooperative agreement or make the first \ngrant under this section.\n    ``(d) Availability of Banked Specimens.--The Director of the \nInstitute shall make available for research conducted under this \nsection banked serum and tissue specimens from clinical research \nregarding ovarian cancer that was funded by the Department of Health \nand Human Services.\n    ``(e) Report.--Not later than the end of fiscal year 2009, and \nannually thereafter, the Director of the Institute shall submit a \nreport to the Congress on the cooperative agreements entered into and \nthe grants made under this section.\n    ``(f) Authorization of Appropriations.--For the purpose of carrying \nout this section, there are authorized to be appropriated $25,000,000 \nfor each of the fiscal years 2009 through 2012, and such sums as may be \nnecessary for each of the fiscal years 2013 through 2019. Such \nauthorization of appropriations is in addition to any other \nauthorization of appropriations that is available for such purpose.''.\n\nSEC. 3. OVARIAN CANCER BIOMARKER CLINICAL TRIAL COMMITTEE.\n\n    Subpart 1 of part C of the Public Health Service Act, as amended by \nsection 2, is further amended by adding at the end the following new \nsection:\n\n``SEC. 417F. OVARIAN CANCER BIOMARKER CLINICAL TRIAL COMMITTEE.\n\n    ``(a) Ovarian Cancer Biomarker Research Committee Established.--The \nDirector of the Institute shall establish an Ovarian Cancer Biomarker \nClinical Trial Committee (in this section referred to as the \n`Committee') to assist the Director to design and implement one or more \nnational clinical trials, in accordance with this section, to determine \nthe utility of using biomarkers validated pursuant to the research \nconducted under section 417E for risk stratification for, and early \ndetection and screening of, ovarian cancer.\n    ``(b) Membership.--\n            ``(1) Number.--The Committee shall consist of 11 voting \n        members and such number of nonvoting members as the Director of \n        the Institute determines appropriate.\n            ``(2) Appointment.--The members of the Committee shall be \n        appointed by the Director of the Institute, in consultation \n        with appropriate national medical societies, research \n        societies, and patient advocate organizations, as follows:\n                    ``(A) Voting members.--The voting members of the \n                Committee shall be appointed by the Director of the \n                Institute as follows:\n                            ``(i) Two patient advocates.\n                            ``(ii) Two national experts in statistical \n                        analysis, clinical trial design, and patient \n                        recruitment.\n                            ``(iii) Two representatives from the \n                        Gynecologic Oncology Group.\n                            ``(iv) One representative from the \n                        Department of Defense Ovarian Cancer Research \n                        Program.\n                            ``(v) Four ovarian cancer researchers.\n                    ``(B) Nonvoting members.--The nonvoting members of \n                the Committee shall include such individuals as the \n                Director of the Institute determines to be appropriate.\n            ``(3) Pay.--Members of the Committee shall serve without \n        pay and those members who are full time officers or employees \n        of the United States shall receive no additional pay by reason \n        of their service on the Committee, except that members of the \n        Committee shall receive travel expenses, including per diem in \n        lieu of subsistence, in accordance with applicable provisions \n        under chapter I of chapter 57 of title 5, United States Code.\n    ``(c) Chairperson.--The voting members of the Committee appointed \nunder subsection (b)(2) shall select a chairperson from among such \nmembers.\n    ``(d) Meetings.--The Committee shall meet at the call of the \nchairperson or upon the request of the Director of the Institute, but \nat least four times each year.\n    ``(e) Clinical Trial Specifications.--In designing and implementing \nthe clinical trials under this section, the Director of the Institute \nshall provide for the following:\n            ``(1) Participation in trial.--To the greatest extent \n        possible, all academic centers, community cancer centers, and \n        individual physician investigators (as defined in subsection \n        (f)) shall have the opportunity to participate in the trials \n        under this section and to enroll women at risk for ovarian \n        cancer in the trials.\n            ``(2) Costs for enrollments.--Subject to the availability \n        of appropriations, all the costs to the centers and offices \n        described in paragraph (1) for enrolling women in the trials \n        under this section shall be reimbursed by the Institute.\n            ``(3) National data center.--A national data center shall \n        be established in and supported by the Institute to conduct \n        statistical analyses of the data derived from the trials under \n        this section and to store such analyses and data.\n            ``(4) Guidelines for medical community.--Data and \n        statistical analyses of the clinical trials under this section \n        shall be used to establish clinical guidelines to provide the \n        medical community with information regarding the use of \n        biomarkers validated pursuant to the research conducted under \n        section 417E for risk stratification for, and early detection \n        and screening of, ovarian cancer.\n    ``(f) Individual Physician Investigator Defined.--For purposes of \nsubsection (e)(1), the term `individual physician investigator' means a \nphysician--\n            ``(1) who is a faculty member at an academic institution or \n        who is in a private medical practice; and\n            ``(2) who provides health care services to women at risk \n        for ovarian cancer.\n    ``(g) Report.--Not later than the end of fiscal year 2009, and \nannually thereafter, the Director of the Institute shall submit a \nreport to the Congress on the activities conducted under this section.\n    ``(h) Authorization of Appropriations.--For the purpose of carrying \nout this section, there are authorized to be appropriated $5,000,000 \nfor each of the fiscal years 2009 through 2012, and such sums as may be \nnecessary for each of the fiscal years 2013 through 2019. Such \nauthorization of appropriations is in addition to any other \nauthorization of appropriations that is available for such purpose.''."
}